IGC Pharma

Historical price data

IGC Pharma is a clinical-stage biotechnology company with a mission to develop novel treatments and AI-driven tools for Alzheimer's disease. Its primary achievement is the advancement of lead candidate IGC-AD1 into a Phase 2 trial (CALMA) targeting Alzheimer's-related agitation, a significant unmet need. The company's strategy uniquely combines therapeutic development of small molecules targeting neuroinflammation and amyloid/tau pathology with a proprietary artificial intelligence platform designed for early prediction and personalized care. Operating as a micro-cap public company, IGC seeks to address a massive and growing market through this integrated, technology-enhanced approach.

Proprietary AI platform (MINT-AD/aha™) designed to transform multimodal data into actionable insights for early Alzheimer's disease prediction and clinical decision support.

IGC faces intense competition in Alzheimer's agitation from recently approved drugs (e.g., brexpiprazole) and other late-stage candidates. Its broader preclinical pipeline enters a crowded disease-modifying therapy field dominated by large pharma. Its AI platform competes with numerous digital health startups and tech giants.